CN114209607A - 一种应用二棕榈酰羟脯氨酸的方法及组合物 - Google Patents
一种应用二棕榈酰羟脯氨酸的方法及组合物 Download PDFInfo
- Publication number
- CN114209607A CN114209607A CN202210027595.4A CN202210027595A CN114209607A CN 114209607 A CN114209607 A CN 114209607A CN 202210027595 A CN202210027595 A CN 202210027595A CN 114209607 A CN114209607 A CN 114209607A
- Authority
- CN
- China
- Prior art keywords
- composition
- parts
- dipalmitoyl hydroxyproline
- alcohol
- polydimethylsiloxane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- QZLXCFQVOCEKSX-NOCHOARKSA-N (2s,4r)-1-hexadecanoyl-4-hexadecanoyloxypyrrolidine-2-carboxylic acid Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@H]1C[C@@H](C(O)=O)N(C(=O)CCCCCCCCCCCCCCC)C1 QZLXCFQVOCEKSX-NOCHOARKSA-N 0.000 title claims abstract description 54
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- 238000000034 method Methods 0.000 title claims abstract description 15
- 239000003921 oil Substances 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 8
- 230000003472 neutralizing effect Effects 0.000 claims abstract description 8
- 239000003755 preservative agent Substances 0.000 claims abstract description 5
- 230000002335 preservative effect Effects 0.000 claims abstract description 5
- 239000002738 chelating agent Substances 0.000 claims abstract description 4
- 239000003906 humectant Substances 0.000 claims abstract description 4
- 239000002562 thickening agent Substances 0.000 claims abstract description 4
- -1 polysiloxane Polymers 0.000 claims description 33
- 229920001577 copolymer Polymers 0.000 claims description 23
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 16
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 14
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 11
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 11
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 11
- 229920006037 cross link polymer Polymers 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 235000021314 Palmitic acid Nutrition 0.000 claims description 8
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 8
- 239000004475 Arginine Substances 0.000 claims description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 6
- BTFJIXJJCSYFAL-UHFFFAOYSA-N icosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 claims description 6
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 6
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 5
- 239000000194 fatty acid Substances 0.000 claims description 5
- 229930195729 fatty acid Natural products 0.000 claims description 5
- 150000004665 fatty acids Chemical class 0.000 claims description 5
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 claims description 4
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 claims description 4
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims description 4
- 150000002191 fatty alcohols Chemical class 0.000 claims description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 4
- 229920001296 polysiloxane Polymers 0.000 claims description 4
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 4
- 229920002554 vinyl polymer Polymers 0.000 claims description 4
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 claims description 3
- 235000021360 Myristic acid Nutrition 0.000 claims description 3
- BSLCSFCXSUCFQN-UHFFFAOYSA-N 1-aminobutane-2,3-diol Chemical compound CC(O)C(O)CN BSLCSFCXSUCFQN-UHFFFAOYSA-N 0.000 claims description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 claims description 2
- IUMSDRXLFWAGNT-UHFFFAOYSA-N Dodecamethylcyclohexasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 IUMSDRXLFWAGNT-UHFFFAOYSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- 239000005639 Lauric acid Substances 0.000 claims description 2
- RGMZNZABJYWAEC-UHFFFAOYSA-N Methyltris(trimethylsiloxy)silane Chemical compound C[Si](C)(C)O[Si](C)(O[Si](C)(C)C)O[Si](C)(C)C RGMZNZABJYWAEC-UHFFFAOYSA-N 0.000 claims description 2
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 2
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 claims description 2
- 229940081733 cetearyl alcohol Drugs 0.000 claims description 2
- 229960000541 cetyl alcohol Drugs 0.000 claims description 2
- 229960002887 deanol Drugs 0.000 claims description 2
- 239000012972 dimethylethanolamine Substances 0.000 claims description 2
- 229940090934 diphenylsiloxy phenyl trimethicone Drugs 0.000 claims description 2
- 229960000735 docosanol Drugs 0.000 claims description 2
- 229940073663 methyl trimethicone Drugs 0.000 claims description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 229940057874 phenyl trimethicone Drugs 0.000 claims description 2
- 229920003217 poly(methylsilsesquioxane) Polymers 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 229940012831 stearyl alcohol Drugs 0.000 claims description 2
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- LINXHFKHZLOLEI-UHFFFAOYSA-N trimethyl-[phenyl-bis(trimethylsilyloxy)silyl]oxysilane Chemical compound C[Si](C)(C)O[Si](O[Si](C)(C)C)(O[Si](C)(C)C)C1=CC=CC=C1 LINXHFKHZLOLEI-UHFFFAOYSA-N 0.000 claims description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 2
- 229960000281 trometamol Drugs 0.000 claims description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 230000001153 anti-wrinkle effect Effects 0.000 abstract description 13
- 206010015946 Eye irritation Diseases 0.000 abstract description 9
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 239000003995 emulsifying agent Substances 0.000 abstract description 4
- 239000000839 emulsion Substances 0.000 abstract description 4
- 230000003712 anti-aging effect Effects 0.000 abstract description 3
- 230000001804 emulsifying effect Effects 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 description 41
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 28
- 210000003491 skin Anatomy 0.000 description 23
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 21
- 108010035532 Collagen Proteins 0.000 description 19
- 102000008186 Collagen Human genes 0.000 description 19
- 229920001436 collagen Polymers 0.000 description 19
- 230000000052 comparative effect Effects 0.000 description 18
- 210000003837 chick embryo Anatomy 0.000 description 16
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 description 14
- 230000000694 effects Effects 0.000 description 12
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 11
- 239000011734 sodium Substances 0.000 description 11
- 229910052708 sodium Inorganic materials 0.000 description 11
- 235000011187 glycerol Nutrition 0.000 description 10
- PQUXFUBNSYCQAL-UHFFFAOYSA-N 1-(2,3-difluorophenyl)ethanone Chemical compound CC(=O)C1=CC=CC(F)=C1F PQUXFUBNSYCQAL-UHFFFAOYSA-N 0.000 description 9
- 239000002537 cosmetic Substances 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- 229940047670 sodium acrylate Drugs 0.000 description 9
- 235000015112 vegetable and seed oil Nutrition 0.000 description 9
- 229940015975 1,2-hexanediol Drugs 0.000 description 8
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 8
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- CMBYOWLFQAFZCP-UHFFFAOYSA-N Hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 description 7
- 244000044822 Simmondsia californica Species 0.000 description 7
- 235000004433 Simmondsia californica Nutrition 0.000 description 7
- 229940100463 hexyl laurate Drugs 0.000 description 7
- 230000007794 irritation Effects 0.000 description 7
- 238000006386 neutralization reaction Methods 0.000 description 7
- 229920002401 polyacrylamide Polymers 0.000 description 7
- 239000000230 xanthan gum Substances 0.000 description 7
- 235000010493 xanthan gum Nutrition 0.000 description 7
- 229920001285 xanthan gum Polymers 0.000 description 7
- 229940082509 xanthan gum Drugs 0.000 description 7
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 6
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 6
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 231100000013 eye irritation Toxicity 0.000 description 6
- 229940042585 tocopherol acetate Drugs 0.000 description 6
- 108010022452 Collagen Type I Proteins 0.000 description 5
- 102000012422 Collagen Type I Human genes 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000003827 upregulation Effects 0.000 description 5
- 230000037303 wrinkles Effects 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 206010015150 Erythema Diseases 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 231100000321 erythema Toxicity 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000009759 skin aging Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 206010040914 Skin reaction Diseases 0.000 description 3
- 229920002385 Sodium hyaluronate Polymers 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229960001631 carbomer Drugs 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 230000035483 skin reaction Effects 0.000 description 3
- 231100000430 skin reaction Toxicity 0.000 description 3
- 229940010747 sodium hyaluronate Drugs 0.000 description 3
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- CCLARULDIPFTCP-BOYHRMMASA-N (2r,3r,4r,5s)-heptane-1,2,3,4,5,6-hexol Chemical compound CC(O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO CCLARULDIPFTCP-BOYHRMMASA-N 0.000 description 2
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 2
- FEBUJFMRSBAMES-UHFFFAOYSA-N 2-[(2-{[3,5-dihydroxy-2-(hydroxymethyl)-6-phosphanyloxan-4-yl]oxy}-3,5-dihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-4-yl)oxy]-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl phosphinite Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(OC2C(C(OP)C(O)C(CO)O2)O)C(O)C(OC2C(C(CO)OC(P)C2O)O)O1 FEBUJFMRSBAMES-UHFFFAOYSA-N 0.000 description 2
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methyl-Pentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 description 2
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102100036213 Collagen alpha-2(I) chain Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 229920002148 Gellan gum Polymers 0.000 description 2
- 101000875067 Homo sapiens Collagen alpha-2(I) chain Proteins 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 229920002305 Schizophyllan Polymers 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 229940048053 acrylate Drugs 0.000 description 2
- 229940110830 beheneth-25 methacrylate Drugs 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- OWBTYPJTUOEWEK-UHFFFAOYSA-N butane-2,3-diol Chemical compound CC(O)C(C)O OWBTYPJTUOEWEK-UHFFFAOYSA-N 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- WWYHAQDAMPXWSI-UHFFFAOYSA-N dodecan-1-ol;methane Chemical compound C.CCCCCCCCCCCCO WWYHAQDAMPXWSI-UHFFFAOYSA-N 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 239000000686 essence Substances 0.000 description 2
- SHZIWNPUGXLXDT-UHFFFAOYSA-N ethyl hexanoate Chemical compound CCCCCC(=O)OCC SHZIWNPUGXLXDT-UHFFFAOYSA-N 0.000 description 2
- 230000004720 fertilization Effects 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 235000010492 gellan gum Nutrition 0.000 description 2
- 239000000216 gellan gum Substances 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 2
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- IIYFAKIEWZDVMP-UHFFFAOYSA-N tridecane Chemical compound CCCCCCCCCCCCC IIYFAKIEWZDVMP-UHFFFAOYSA-N 0.000 description 2
- RSJKGSCJYJTIGS-UHFFFAOYSA-N undecane Chemical compound CCCCCCCCCCC RSJKGSCJYJTIGS-UHFFFAOYSA-N 0.000 description 2
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- NRTKYSGFUISGRQ-UHFFFAOYSA-N (3-heptanoyloxy-2,2-dimethylpropyl) heptanoate Chemical compound CCCCCCC(=O)OCC(C)(C)COC(=O)CCCCCC NRTKYSGFUISGRQ-UHFFFAOYSA-N 0.000 description 1
- MXOAEAUPQDYUQM-QMMMGPOBSA-N (S)-chlorphenesin Chemical compound OC[C@H](O)COC1=CC=C(Cl)C=C1 MXOAEAUPQDYUQM-QMMMGPOBSA-N 0.000 description 1
- NKJOXAZJBOMXID-UHFFFAOYSA-N 1,1'-Oxybisoctane Chemical compound CCCCCCCCOCCCCCCCC NKJOXAZJBOMXID-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- 229940035437 1,3-propanediol Drugs 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- OVYMWJFNQQOJBU-UHFFFAOYSA-N 1-octanoyloxypropan-2-yl octanoate Chemical compound CCCCCCCC(=O)OCC(C)OC(=O)CCCCCCC OVYMWJFNQQOJBU-UHFFFAOYSA-N 0.000 description 1
- WAYINTBTZWQNSN-UHFFFAOYSA-N 11-methyldodecyl 3,5,5-trimethylhexanoate Chemical compound CC(C)CCCCCCCCCCOC(=O)CC(C)CC(C)(C)C WAYINTBTZWQNSN-UHFFFAOYSA-N 0.000 description 1
- ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 1
- 229940043268 2,2,4,4,6,8,8-heptamethylnonane Drugs 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- DBHODFSFBXJZNY-UHFFFAOYSA-N 2,4-dichlorobenzyl alcohol Chemical compound OCC1=CC=C(Cl)C=C1Cl DBHODFSFBXJZNY-UHFFFAOYSA-N 0.000 description 1
- NLMKTBGFQGKQEV-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hexadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO NLMKTBGFQGKQEV-UHFFFAOYSA-N 0.000 description 1
- NFIHXTUNNGIYRF-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate Chemical compound CCCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCCC NFIHXTUNNGIYRF-UHFFFAOYSA-N 0.000 description 1
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 description 1
- GTJOHISYCKPIMT-UHFFFAOYSA-N 2-methylundecane Chemical compound CCCCCCCCCC(C)C GTJOHISYCKPIMT-UHFFFAOYSA-N 0.000 description 1
- KOZZOZYINRDZOU-UHFFFAOYSA-N 2-octadecoxyethyl 2-methylprop-2-enoate Chemical compound CCCCCCCCCCCCCCCCCCOCCOC(=O)C(C)=C KOZZOZYINRDZOU-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- UIVPNOBLHXUKDX-UHFFFAOYSA-N 3,5,5-trimethylhexyl 3,5,5-trimethylhexanoate Chemical compound CC(C)(C)CC(C)CCOC(=O)CC(C)CC(C)(C)C UIVPNOBLHXUKDX-UHFFFAOYSA-N 0.000 description 1
- RMTFNDVZYPHUEF-XZBKPIIZSA-N 3-O-methyl-D-glucose Chemical compound O=C[C@H](O)[C@@H](OC)[C@H](O)[C@H](O)CO RMTFNDVZYPHUEF-XZBKPIIZSA-N 0.000 description 1
- PBFGMXZRJIUGKU-UHFFFAOYSA-N 3-decanoyloxybutyl decanoate Chemical compound CCCCCCCCCC(=O)OCCC(C)OC(=O)CCCCCCCCC PBFGMXZRJIUGKU-UHFFFAOYSA-N 0.000 description 1
- ANZUDYZHSVGBRF-UHFFFAOYSA-N 3-ethylnonane-1,2,3-triol Chemical compound CCCCCCC(O)(CC)C(O)CO ANZUDYZHSVGBRF-UHFFFAOYSA-N 0.000 description 1
- XPFCZYUVICHKDS-UHFFFAOYSA-N 3-methylbutane-1,3-diol Chemical compound CC(C)(O)CCO XPFCZYUVICHKDS-UHFFFAOYSA-N 0.000 description 1
- FVKRIDSRWFEQME-UHFFFAOYSA-N 3-methylbutyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCC(C)C FVKRIDSRWFEQME-UHFFFAOYSA-N 0.000 description 1
- LFESLSYSZQYEIZ-UHFFFAOYSA-N 3-octanoyloxybutyl octanoate Chemical compound CCCCCCCC(=O)OCCC(C)OC(=O)CCCCCCC LFESLSYSZQYEIZ-UHFFFAOYSA-N 0.000 description 1
- XXBAQTDVRLRXEV-UHFFFAOYSA-N 3-tetradecoxypropan-1-ol Chemical compound CCCCCCCCCCCCCCOCCCO XXBAQTDVRLRXEV-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- FBNAWLJSQORPAX-UHFFFAOYSA-N 4-methyl-3-propan-2-ylphenol Chemical compound CC(C)C1=CC(O)=CC=C1C FBNAWLJSQORPAX-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical class [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000197194 Bulla Species 0.000 description 1
- LSAACDIRVQTDAU-UHFFFAOYSA-N C(CC(O)(C(=O)O)CC(=O)O)(=O)O.C(CCCCCCC)C(CCCCCCCCCCC)O.C(CCCCCCC)C(CCCCCCCCCCC)O.C(CCCCCCC)C(CCCCCCCCCCC)O Chemical compound C(CC(O)(C(=O)O)CC(=O)O)(=O)O.C(CCCCCCC)C(CCCCCCCCCCC)O.C(CCCCCCC)C(CCCCCCCCCCC)O.C(CCCCCCC)C(CCCCCCCCCCC)O LSAACDIRVQTDAU-UHFFFAOYSA-N 0.000 description 1
- 240000001548 Camellia japonica Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000206575 Chondrus crispus Species 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- XTJFFFGAUHQWII-UHFFFAOYSA-N Dibutyl adipate Chemical compound CCCCOC(=O)CCCCC(=O)OCCCC XTJFFFGAUHQWII-UHFFFAOYSA-N 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical compound [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 240000000950 Hippophae rhamnoides Species 0.000 description 1
- 235000003145 Hippophae rhamnoides Nutrition 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- SGVYKUFIHHTIFL-UHFFFAOYSA-N Isobutylhexyl Natural products CCCCCCCC(C)C SGVYKUFIHHTIFL-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 235000018330 Macadamia integrifolia Nutrition 0.000 description 1
- 240000000912 Macadamia tetraphylla Species 0.000 description 1
- 235000003800 Macadamia tetraphylla Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- OQILCOQZDHPEAZ-UHFFFAOYSA-N Palmitinsaeure-octylester Natural products CCCCCCCCCCCCCCCC(=O)OCCCCCCCC OQILCOQZDHPEAZ-UHFFFAOYSA-N 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 244000239204 Plantago lanceolata Species 0.000 description 1
- 235000010503 Plantago lanceolata Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 241000727169 Prinsepia utilis Species 0.000 description 1
- 235000019774 Rice Bran oil Nutrition 0.000 description 1
- 240000000528 Ricinus communis Species 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 240000008530 Rosa canina Species 0.000 description 1
- 235000000539 Rosa canina Nutrition 0.000 description 1
- 235000010337 Rosa dumalis Nutrition 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 241001135917 Vitellaria paradoxa Species 0.000 description 1
- FSEJJKIPRNUIFL-UHFFFAOYSA-N [2,2-bis(hydroxymethyl)-3-octadecanoyloxypropyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(CO)(CO)COC(=O)CCCCCCCCCCCCCCCCC FSEJJKIPRNUIFL-UHFFFAOYSA-N 0.000 description 1
- DRRMRHKHTQRWMB-UHFFFAOYSA-N [3-(2-ethylhexanoyloxy)-2,2-bis(2-ethylhexanoyloxymethyl)propyl] 2-ethylhexanoate Chemical compound CCCCC(CC)C(=O)OCC(COC(=O)C(CC)CCCC)(COC(=O)C(CC)CCCC)COC(=O)C(CC)CCCC DRRMRHKHTQRWMB-UHFFFAOYSA-N 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 229920006322 acrylamide copolymer Polymers 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000010478 argan oil Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- BQMNFPBUAQPINY-UHFFFAOYSA-N azane;2-methyl-2-(prop-2-enoylamino)propane-1-sulfonic acid Chemical compound [NH4+].[O-]S(=O)(=O)CC(C)(C)NC(=O)C=C BQMNFPBUAQPINY-UHFFFAOYSA-N 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 229940091509 beheneth-20 Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- HGKOWIQVWAQWDS-UHFFFAOYSA-N bis(16-methylheptadecyl) 2-hydroxybutanedioate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CC(O)C(=O)OCCCCCCCCCCCCCCCC(C)C HGKOWIQVWAQWDS-UHFFFAOYSA-N 0.000 description 1
- SWQUTKGVXGTROS-UHFFFAOYSA-N bis(2-ethoxyethyl) butanedioate Chemical compound CCOCCOC(=O)CCC(=O)OCCOCC SWQUTKGVXGTROS-UHFFFAOYSA-N 0.000 description 1
- PXTQQOLKZBLYDY-UHFFFAOYSA-N bis(2-ethylhexyl) carbonate Chemical compound CCCCC(CC)COC(=O)OCC(CC)CCCC PXTQQOLKZBLYDY-UHFFFAOYSA-N 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 229940114374 butylene glycol dicaprylate Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000000828 canola oil Substances 0.000 description 1
- 235000019519 canola oil Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940056318 ceteth-20 Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960003993 chlorphenesin Drugs 0.000 description 1
- 229940074992 chondrus crispus extract Drugs 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 235000018597 common camellia Nutrition 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229940100539 dibutyl adipate Drugs 0.000 description 1
- 229960004698 dichlorobenzyl alcohol Drugs 0.000 description 1
- 229940119676 diethoxyethyl succinate Drugs 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- 229940031569 diisopropyl sebacate Drugs 0.000 description 1
- PKPOVTYZGGYDIJ-UHFFFAOYSA-N dioctyl carbonate Chemical compound CCCCCCCCOC(=O)OCCCCCCCC PKPOVTYZGGYDIJ-UHFFFAOYSA-N 0.000 description 1
- XFKBBSZEQRFVSL-UHFFFAOYSA-N dipropan-2-yl decanedioate Chemical compound CC(C)OC(=O)CCCCCCCCC(=O)OC(C)C XFKBBSZEQRFVSL-UHFFFAOYSA-N 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- XJFGDLJQUJQUEI-UHFFFAOYSA-N dodecyl decanoate dodecyl octanoate Chemical compound CCCCCCCCCCCCOC(=O)CCCCCCC.CCCCCCCCCCCCOC(=O)CCCCCCCCC XJFGDLJQUJQUEI-UHFFFAOYSA-N 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- GADGVXXJJXQRSA-UHFFFAOYSA-N ethenyl 8-methylnonanoate Chemical compound CC(C)CCCCCCC(=O)OC=C GADGVXXJJXQRSA-UHFFFAOYSA-N 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- GJQLBGWSDGMZKM-UHFFFAOYSA-N ethylhexyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(CC)CCCCC GJQLBGWSDGMZKM-UHFFFAOYSA-N 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229920000370 gamma-poly(glutamate) polymer Polymers 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940087068 glyceryl caprylate Drugs 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 239000008169 grapeseed oil Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- KWLMIXQRALPRBC-UHFFFAOYSA-L hectorite Chemical compound [Li+].[OH-].[OH-].[Na+].[Mg+2].O1[Si]2([O-])O[Si]1([O-])O[Si]([O-])(O1)O[Si]1([O-])O2 KWLMIXQRALPRBC-UHFFFAOYSA-L 0.000 description 1
- 229910000271 hectorite Inorganic materials 0.000 description 1
- XJNUECKWDBNFJV-UHFFFAOYSA-N hexadecyl 2-ethylhexanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC XJNUECKWDBNFJV-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 235000019866 hydrogenated palm kernel oil Nutrition 0.000 description 1
- 229920006007 hydrogenated polyisobutylene Polymers 0.000 description 1
- 239000008173 hydrogenated soybean oil Substances 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 229940078565 isoamyl laurate Drugs 0.000 description 1
- VKPSKYDESGTTFR-UHFFFAOYSA-N isododecane Natural products CC(C)(C)CC(C)CC(C)(C)C VKPSKYDESGTTFR-UHFFFAOYSA-N 0.000 description 1
- 229940100554 isononyl isononanoate Drugs 0.000 description 1
- KUVMKLCGXIYSNH-UHFFFAOYSA-N isopentadecane Natural products CCCCCCCCCCCCC(C)C KUVMKLCGXIYSNH-UHFFFAOYSA-N 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229940060384 isostearyl isostearate Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000010487 meadowfoam seed oil Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 229940105132 myristate Drugs 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- RGUVUPQQFXCJFC-UHFFFAOYSA-N n-hydroxyoctanamide Chemical compound CCCCCCCC(=O)NO RGUVUPQQFXCJFC-UHFFFAOYSA-N 0.000 description 1
- 239000010466 nut oil Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- AEIJTFQOBWATKX-UHFFFAOYSA-N octane-1,2-diol Chemical compound CCCCCCC(O)CO AEIJTFQOBWATKX-UHFFFAOYSA-N 0.000 description 1
- 229940060184 oil ingredients Drugs 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920001748 polybutylene Polymers 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 229920005614 potassium polyacrylate Polymers 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 229940116987 ppg-3 myristyl ether Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108010029690 procollagenase Proteins 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000008165 rice bran oil Substances 0.000 description 1
- 239000010667 rosehip oil Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229940057910 shea butter Drugs 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 239000000661 sodium alginate Chemical class 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 1
- 235000019982 sodium hexametaphosphate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 238000012430 stability testing Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940073743 steareth-20 methacrylate Drugs 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 235000020238 sunflower seed Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- FJFYFBRNDHRTHL-UHFFFAOYSA-N tris(8-methylnonyl) benzene-1,2,4-tricarboxylate Chemical compound CC(C)CCCCCCCOC(=O)C1=CC=C(C(=O)OCCCCCCCC(C)C)C(C(=O)OCCCCCCCC(C)C)=C1 FJFYFBRNDHRTHL-UHFFFAOYSA-N 0.000 description 1
- SMYKBXMWXCZOLU-UHFFFAOYSA-N tris-decyl benzene-1,2,4-tricarboxylate Chemical compound CCCCCCCCCCOC(=O)C1=CC=C(C(=O)OCCCCCCCCCC)C(C(=O)OCCCCCCCCCC)=C1 SMYKBXMWXCZOLU-UHFFFAOYSA-N 0.000 description 1
- 229940048081 trisodium ethylenediamine disuccinate Drugs 0.000 description 1
- QEHXDDFROMGLSP-VDBFCSKJSA-K trisodium;(2s)-2-[2-[[(1s)-1-carboxy-2-carboxylatoethyl]amino]ethylamino]butanedioate Chemical compound [Na+].[Na+].[Na+].OC(=O)C[C@@H](C([O-])=O)NCCN[C@H](C([O-])=O)CC([O-])=O QEHXDDFROMGLSP-VDBFCSKJSA-K 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
Abstract
本发明公开了一种应用二棕榈酰羟脯氨酸的方法,方法为将二棕榈酰羟脯氨酸以中和形式应用于组合物中。同时公开了一种应用二棕榈酰羟脯氨酸的组合物,组合物中的二棕榈酰羟脯氨酸以中和形式应用,按重量份数计包含以下组分:油类0.1‑50份、二棕榈酰羟脯氨酸0.08‑5份、螯合剂0.001‑0.2份、保湿剂0.01‑30份、增稠剂0.01‑5.0份、中和剂0.001‑7.5份、防腐剂0.01‑3份以及水20‑99份。属于化妆品技术领域,本发明公开的方法及组合物,既能发挥二棕榈酰羟脯氨酸良好的抗皱抗衰功效,又能提升人体皮肤安全性,降低眼部刺激性。同时中和后的二棕榈酰羟脯氨酸具备一定的乳化能力,可以在减少或不加传统乳化剂的基础上,制备出稳定的乳状液,节约了生产成本,具有良好的市场应用前景。
Description
技术领域
本发明公开了一种在化妆品中应用合成原料的方法及组合物,具体地说,是一种应用二棕榈酰羟脯氨酸的方法及组合物,属于化妆品技术领域。
背景技术
众所周知,肌肤老化分自然老化和环境因素导致的老化,一般25岁以后,女性的皮肤的新陈代谢就会日趋缓慢,角质层会渐渐堆积变厚。除了年龄会影响皮肤状况,由于工作、生活压力导致的体内荷尔蒙的变化,环境的污染,紫外线的辐射,不良的饮食习惯以及不恰当的肌肤保养方式均会影响皮肤健康,导致大量自由基的生成,这些活跃的分子基团会引发一系列自由基反应,造成细胞的损伤甚至死亡,从而使肌肤加速衰老。坚持长期正确使用有效的抗衰紧致护肤品,在一定程度上可以有效延缓皮肤衰老的速度。随着经济发展,人们对化妆品需求上升,抗皱化妆品成为备受消费者关注的对象。
在众多抗皱添加剂中,二棕榈酰羟脯氨酸作为羟脯氨酸的载体可以单一形式或与任何有抗皱、减缓皮肤松弛,提升肌肤弹性作用的产品配合使用,在抗皱类化妆品中有很大的应用潜力。二棕榈酰羟脯氨酸能刺激胶原纤维的紧缩,保护弹性纤维对抗酶的降解,捕捉自由基,保护皮肤细胞(如纤维原细胞),修复皮肤抗老化防御(增加TIMPs),抑制MMPs的活性,保护胶原质和DEJ结构,具有比维生素C更强的刺激胶原纤维收缩作用和抑制弹性蛋白酶活性的作用,具有理想的皮肤亲和力和刺激胶原纤维收缩,恢复皮肤紧实度作用,并能有效保护弹性蛋白,清除氧自由基,增加皮肤中水份含量等作用。二棕榈酰羟脯氨酸作为油溶性原料,其使用方法通常是与油类互溶加至组合物中,同时添加乳化剂,将其和油类乳化成稳定的乳状液。二棕榈酰羟脯氨酸以这种使用方式添加至组合物中,对人体皮肤具有一定的刺激性,且随着添加量增加,其刺激性也会增加。
因此,研究一种应用二棕榈酰羟脯氨酸的方法,使得二棕榈酰羟脯氨酸在应用过程中既能发挥良好的抗皱抗衰功效,又能提升人体皮肤安全性,降低眼部刺激性十分有必要。
发明内容
针对上述不足,本发明的目的是提供一种应用二棕榈酰羟脯氨酸的方法及组合物品,既能发挥二棕榈酰羟脯氨酸良好的抗皱抗衰功效,又能提升人体皮肤安全性,同时中和后的二棕榈酰羟脯氨酸具备一定的乳化能力,可以在减少或不加传统乳化剂的基础上,制备出稳定的乳状液。
为此,本发明提供的第一个技术方案是这样的:
一种应用二棕榈酰羟脯氨酸的方法,所述方法为将二棕榈酰羟脯氨酸以中和形式应用于组合物中。
本申请同时公开了一种应用二棕榈酰羟脯氨酸的组合物,所述组合物中的二棕榈酰羟脯氨酸以中和形式应用,按重量份数计包含以下组分:油类0.1-50份、二棕榈酰羟脯氨酸0.08-5份、螯合剂0.001-0.2份、保湿剂0.01-30份、增稠剂0.01-5.0份、中和剂0.001-7.5份、防腐剂0.01-3份以及水20-99份。
作为优选,所述油类为椰油醇-辛酸酯/癸酸酯、生育酚(维生素E)、生育酚乙酸酯、丙二醇二辛酸酯/二癸酸酯、新戊二醇二庚酸酯、甘油三(乙基己酸)酯、霍霍巴籽油、角鲨烷、白池花籽油、稻糠油、澳洲坚果籽油、油橄榄果油、葡萄籽油、月桂酸己酯、氢化聚异丁烯、矿油、碳酸二乙基己酯、碳酸二辛酯、燕麦仁油、月桂酸异戊酯、丁二醇二辛酸/二癸酸酯、二辛基醚、己二酸二丁酯、癸二酸二异丙酯、异硬脂醇、琥珀酸二乙氧基乙酯、异壬酸异壬酯、辛酸/癸酸甘油三酯、鲸蜡醇乙基己酸酯、异十三醇异壬酸酯、二C12-13醇苹果酸酯、刺阿干树仁油、牛油果树果脂、甜扁桃油、氢化棕榈仁油、C10-18脂酸甘油三酯类、矿脂、季戊四醇四(乙基己酸)酯、氢化聚癸烯、C12-15醇苯甲酸酯、液体石蜡、棕榈酸异丙酯、肉豆蔻酸异丙酯、棕榈酸乙基己酯、异硬脂醇异硬脂酸酯、十三烷醇偏苯三酸酯、异十二烷、异十六烷、小麦胚芽油、蓖麻籽油、亚麻籽油、鳄梨油、辛基十二醇、辛酸/癸酸/肉豆蔻酸/硬脂酸甘油三酯、三(辛基十二烷醇)柠檬酸酯、C13-14异链烷烃、向日葵籽油、氢化大豆油、低芥酸菜子油、聚异丁烯、狗牙蔷薇果油、辛基十二醇肉豆蔻酸酯、季戊四醇二硬脂酸酯、PPG-3肉豆蔻醇醚、氢化松脂酸甲酯、二异硬脂醇苹果酸酯、椰子油、棕榈油、月见草油、山茶籽油、大豆油、沙棘籽油、扁核木油、C12-13醇乳酸酯、三异癸醇偏苯三酸酯、十一烷、十三烷、氢化蓖麻油、青刺果油中的一种或多种。
作为优选,所述螯合剂为EDTA二钠、EDTA三钠、EDTA四钠、六偏磷酸钠、乙二胺二琥珀酸三钠中的一种或多种。
作为优选,所述保湿剂为甘油、1,3-丁二醇、1,2-己二醇、1,2-戊二醇、2,3-丁二醇、双丙甘醇、甲基丙二醇、丙二醇、1,3-丙二醇、甲基葡糖醇聚醚-10、甲基葡糖醇聚醚-20、聚甘油-10、山梨醇、甘油聚醚-26、聚乙二醇-8、PEG/PPG/聚丁二醇-8/5/3甘油、双甘油、PPG-10甲基葡糖醚、聚甘油-3、小核菌胶、水解小核菌胶、透明质酸、透明质酸钠、水解透明质酸钠、乙酰化透明质酸钠、乙酰壳糖胺、琥珀酰聚糖、异戊二醇、聚谷氨酸钠、皱波角叉菜提取物、皱波角叉菜中的一种或多种。
作为优选,所述增稠剂为黄原胶、卡拉胶、纤维素、纤维素胶、羟乙基纤维素、微晶纤维素、羟丙基甲基纤维素、卡波姆、丙烯酸(酯)类共聚物、丙烯酸(酯)类/C10-30烷醇丙烯酸酯交联聚合物、聚丙烯酸钠、聚丙烯酸钾、聚丙烯酸酯交联聚合物-6、丙烯酸(酯)类共聚物钠、PEG-240/HDI共聚物双-癸基十四醇聚醚-20醚、丙烯酰胺/丙烯酸铵共聚物、聚丙烯酸酯-13、丙烯酸羟乙酯/丙烯酰二甲基牛磺酸钠共聚物、硅酸铝镁、膨润土、丙烯酰二甲基牛磺酸铵/VP共聚物、丙烯酸(酯)类/异癸酸乙烯酯交联聚合物、藻酸钠、聚丙烯酰基二甲基牛磺酸铵、聚丙烯酸、聚丙烯酰基二甲基牛磺酸钠、丙烯酸(酯)类交联聚合物钠-2、丙烯酸钠/丙烯酰二甲基牛磺酸钠共聚物、聚丙烯酰胺、卡波姆钠、丙烯酸(酯)类/鲸蜡醇聚醚-20甲基丙烯酸酯共聚物、丙烯酸(酯)类/棕榈油醇聚醚-25丙烯酸酯共聚物、结冷胶、丙烯酸(酯)类/丙烯酰胺共聚物、丙烯酸(酯)类/硬脂醇聚醚-20甲基丙烯酸酯交联聚合物、丙烯酰胺/丙烯酰基二甲基牛磺酸钠共聚物、聚乙二醇-14M、聚丙烯酸钠接枝淀粉、甘油聚丙烯酸酯、丙烯酸(酯)类/山嵛醇聚醚-25甲基丙烯酸酯共聚物、改性玉米淀粉、卡波姆钠、司拉氯铵水辉石中的一种或多种。
作为优选,所述中和剂为氢氧化钾、氢氧化钠、精氨酸、氨丁三醇、氨甲基丙醇、三乙醇胺、氨甲基丙二醇、二甲基乙醇胺、二乙基乙醇胺中的一种或多种。
作为优选,所述防腐剂为辛酰羟肟酸、乙基己基甘油、氯苯甘醚、苯氧乙醇、羟苯甲酯、羟苯乙酯、苯甲酸钠、山梨酸钾、o-伞花烃-5-醇、甘油辛酸酯、二氯苯甲醇、1,2-己二醇、1,2-戊二醇、对羟基苯乙酮、辛甘醇中的一种或多种。
作为优选,所述组合物中二棕榈酰羟脯氨酸与中和剂的的重量比为1:(0.002-2.5)。
进一步地,所述组合物中二棕榈酰羟脯氨酸与中和剂的的重量比为1:(0.004-2.1)。
作为优选,按重量份数计还包括聚硅氧烷0.01-20份。
进一步地,所述聚硅氧烷为环五聚二甲基硅氧烷、聚二甲基硅氧烷、环己硅氧烷、聚二甲基硅氧烷醇、聚甲基硅倍半氧烷、聚二甲基硅氧烷交联聚合物、辛基聚甲基硅氧烷、乙烯基聚二甲基硅氧烷交联聚合物、苯基聚三甲基硅氧烷、硬脂基聚二甲硅氧烷、二苯基甲硅烷氧基苯基聚三甲基硅氧烷、丙烯酸(酯)类/聚三甲基硅氧烷甲基丙烯酸酯共聚物、乙烯基聚二甲基硅氧烷/聚甲基硅氧烷硅倍半氧烷交联聚合物、鲸蜡基聚二甲基硅氧烷、聚硅氧烷-11、聚甲基硅氧烷、二聚硅氧烷、甲基聚三甲基硅氧烷中的一种或多种。
作为优选,按重量份数计还包含脂肪醇0.01-10份。
进一步地,所述脂肪醇为鲸蜡醇、硬脂醇、山嵛醇、鲸蜡硬脂醇、花生醇、椰油醇、C12-16醇、C14-22醇、C20-22醇中的一种或多种
作为优选,按重量份数计还包含脂肪酸0.01-5份。
进一步地,所述脂肪酸为月桂酸、棕榈酸、肉豆蔻酸、硬脂酸中的一种或多种。
与现有技术相比,本发明具有的有益效果如下:
1、本发明所公布的应用二棕榈酰羟脯氨酸的方法,通过将二棕榈酰羟脯氨酸以中和的方式进行应用,一方面能够减少因为在化妆品组合物中添加二棕榈酰羟脯氨酸而使得组合物的稳定性降低的情况发生,另一方面还可以提升人体皮肤安全性,减少因为在化妆品组合物中添加二棕榈酰羟脯氨酸而使得组合物对皮肤产生刺激的情况发生。
2、本发明所公布的应用二棕榈酰羟脯氨酸的组合物,成分类型简单,易于制备,安全温和,同时中和后的二棕榈酰羟脯氨酸具备了一定的乳化能力,可以在减少或不加传统乳化剂的基础上,制备出稳定的乳状液,节约了生产成本,具有良好的市场应用前景。
具体实施方式
下面结合具体实施方式,对本发明的权利要求做进一步的详细说明,但不构成对本发明的任何限制,任何人在本发明权利要求保护范围内所做的有限次的修改,仍在本发明的权利要求保护范围之内。
下述实施例与对比例中的组分原料无特殊说明均为市售。
实施例1:
一种应用二棕榈酰羟脯氨酸的组合物,包含有如下组分:生育酚乙酸酯0.6克、霍霍巴籽油9克、月桂酸己酯6克、二棕榈酰羟脯氨酸2.49克、棕榈酸0.51克、水249.21克、EDTA二钠0.06克、甘油18克、黄原胶0.45克、聚丙烯酰基二甲基牛磺酸铵1.5克、精氨酸0.18克、对羟基苯乙酮1.5克、1,2-己二醇1.5克、丁二醇9克。
实施例2:
一种应用二棕榈酰羟脯氨酸的组合物,包含有如下组分:生育酚乙酸酯0.6克、霍霍巴籽油9克、月桂酸己酯6克、二棕榈酰羟脯氨酸2.49克、棕榈酸0.51克、水249.03克、EDTA二钠0.06克、甘油18克、黄原胶0.45克、聚丙烯酰基二甲基牛磺酸铵1.5克、精氨酸0.36克、对羟基苯乙酮1.5克、1,2-己二醇1.5克、丁二醇9克。
实施例3:
一种应用二棕榈酰羟脯氨酸的组合物,包含有如下组分:生育酚乙酸酯0.6克、霍霍巴籽油9克、月桂酸己酯6克、二棕榈酰羟脯氨酸2.49克、棕榈酸0.51克、水248.85克、EDTA二钠0.06克、甘油18克、黄原胶0.45克、聚丙烯酰基二甲基牛磺酸铵1.5克、精氨酸0.54克、对羟基苯乙酮1.5克、1,2-己二醇1.5克、丁二醇9克。
实施例4:
一种应用二棕榈酰羟脯氨酸的组合物,包含有如下组分:生育酚乙酸酯0.6克、霍霍巴籽油9克、月桂酸己酯6克、二棕榈酰羟脯氨酸2.49克、棕榈酸0.51克、水248.67克、EDTA二钠0.06克、甘油18克、黄原胶0.45克、聚丙烯酰基二甲基牛磺酸铵1.5克、精氨酸0.72克、对羟基苯乙酮1.5克、1,2-己二醇1.5克、丁二醇9克。
对比例1:
一种应用二棕榈酰羟脯氨酸的组合物,包含有如下组分:生育酚乙酸酯0.6克、霍霍巴籽油9克、月桂酸己酯6克、二棕榈酰羟脯氨酸2.49克、棕榈酸0.51克、水249.39克、EDTA二钠0.06克、甘油18克、黄原胶0.45克、聚丙烯酰基二甲基牛磺酸铵1.5克、对羟基苯乙酮1.5克、1,2-己二醇1.5克、丁二醇9克。
对比例2:
一种应用二棕榈酰羟脯氨酸的组合物,包含有如下组分:生育酚乙酸酯0.6克、霍霍巴籽油9克、月桂酸己酯6克、二棕榈酰羟脯氨酸4.98克、棕榈酸1.02克、水246.39克、EDTA二钠0.06克、甘油18克、黄原胶0.45克、聚丙烯酰基二甲基牛磺酸铵1.5克、对羟基苯乙酮1.5克、1,2-己二醇1.5克、丁二醇9克。
表1、实施例1-4及对比例1-2组分表
为了证明本发明的效果,对上述实施例及对比例的稳定性、安全性和功效性进行验证,通过高低温稳定性测试、斑贴试验、鸡胚实验、细胞毒性实验、抗皱功效测试等测试来验证说明书中所描述的效果,证明依据本发明所提供的技术方案得到的产品状态稳定、具有抗皱功效,可以有效提升人体皮肤安全性,降低眼部刺激性。
1、稳定性测试:
实验方法:针对实施例1-4与对比例1-2中的样品分别进行光照、耐热、耐寒、常温条件下的稳定性测试。
(1)、光照:将实施例1-4与对比例1-2的测试样品放于光照处,观察样品第0、1、2、4、8周的变化,是否发生变化。
表2样品在光照条件下的测试结果
其中,√表示样品状态正常,下同。
从表中可以看出,经过8周时间,实施例1-2与对比例1-2的精华乳在光照条件下气味有轻微差异,实施例3-4在光照条件下状态稳定,没有发生状态变化。说明实施例3-4光照条件下,稳定性优于实施例1-2与对比例1-2。
(2)、耐寒:将实施例1-4与对比例1-2的测试样品置于-15℃培养箱内低温测试,观察样品变化。
表3样品的耐寒测试结果
从表中可以看出,经过8周时间,实施例1-4与对比例1-2的精华乳在-15℃条件下状态稳定,没有发生状态变化,说明其耐寒效果佳。
(3)、耐热:将实施例1-4与对比例1-2的测试样品置于45℃培养箱内高温测试,观察样品变化;
表4样品的耐热测试结果
从表中可以看出,经过8周时间,对比例1-2的精华乳在45℃条件下颜色和气味与常温条件对比有轻微差异,实施例1-2仅气味有轻微差异,实施例3-4没有发生状态变化,说明其耐热效果佳。相对对比例1-2,有中和的耐热效果更佳,且随中和度上升,其耐热效果更好。
(4)、常温:将实施例1-4与对比例1-2的测试样品放于常温中,观察样品变化;
表5样品的常温测试结果
从表中可以看出,经过8周时间,实施例1-4与对比例1-2的精华乳在常温条件下状态稳定,没有发生状态变化,说明其在常温条件下具有较好的稳定性。
2、体外眼刺激试验-鸡胚绒毛***试验:
2.1、试验材料
2.1.1、鸡胚:SPF级。
2.1.2、其它材料:电子计时器。
2.2、试验条件:孵化箱温度37.5℃±0.5℃,孵化箱相对湿度55%-70%。
2.3、对照:阴性对照为0.9%的NaCl溶液,阳性对照为0.1mol/LNaOH溶液。
2.4、试验步骤
2.4.1、CAM制备:购买0天龄以内的鸡胚,气室朝上运输至实验室。鸡胚到货后需立即运回,气室朝上置于孵化箱中孵化;第2天时,将鸡胚放平;孵化到4天时照蛋检查,在受精位置做标记,于气孔另一端开一小孔,用注射器抽取蛋清2.5-3ml后用石蜡封口,在受精位置的正上方开一个1*1cm2的小口,检查鸡胚发育情况,弃去未发育或发育不好的鸡胚,检查完毕后用保鲜膜将此开口封住,放回孵化箱继续孵化,每天观察鸡胚发育情况;孵化到14天开始试验。
2.4.2、受试物制备:受试物以未稀释原样终点评价法进行试验;阳性对照和阴性对照采用相同的操作过程。
2.4.3、正式试验:每组至少6只鸡胚,取受试物原样0.4mL直接滴加在CAM表面,作用30min后,观察CAM反应情况,记录反应的程度。
2.4.4、评分程度标准:有充血0.5分;出血、凝血和血管融解的轻微现象0.5分;轻度1分;中度2分;重度3分。
2.4.5、计算终点评分(ES):每只鸡胚计分=每只鸡胚观察到的充血、出血、凝血和血管融解程度的和;ES=6只鸡胚得分的数学总和。根据ES数值对受试物眼刺激进行分类。表2.4.6、根据计算的ES数值对受试物眼刺激性进行分类
表6、根据ES数值对受试物眼刺激性的分类标准
终点评分 | 刺激性分类 |
0≤ES<6 | 无眼刺激性 |
6≤ES≤12 | 轻眼刺激性 |
12<ES<16 | 中眼刺激性 |
ES≥16 | 强眼刺激性 |
表7、鸡胚绒毛***试验结果
由上可知,在不中和的情况下,随二棕榈酰羟脯氨酸浓度增加,对眼刺激性增大;有中和的对比无中和的,鸡胚分数更低,对眼刺激性减小,安全性更佳。
3、人体皮肤封闭型斑贴试验
3.1、测试样品:利用实施例1-4与对比例1-2样品制备例制备的护肤品。
3.2、受试者:选取健康志愿者31名,年龄18~24岁,受试者应符合志愿者入选标准,无过敏性皮炎史,且前一个月也未使用刺激性产品。
3.3、斑试方法:选用合格的斑试器材,以封闭型斑贴试验方法,将受试物约0.020g-0.025g置于斑试器内,外用低致敏胶带贴敷于受试者手臂,24小时后去除受试物,分别于去除后0.5、24、48小时观察皮肤反应,按《化妆品安全技术规范》2015年版中皮肤反应分级标准记录其结果。
表8、鉴定标准表
等级 | 鉴定标准 |
0 | 无刺激、无红斑 |
1 | 轻度红斑 |
2 | 红斑 |
3 | 红斑、丘疹、水泡 |
4 | 严重附浮肿、大泡 |
表9、皮肤反应结果记录表
由封闭型斑贴测试结果可知,不中和的情况下,随二棕榈酰羟脯氨酸浓度增加,对人体皮肤刺激性增大;有中和的安全性更佳,且随中和度增加,安全性更佳。
4、细胞抗皱测试:Ⅰ型胶原蛋白含量测定
4.1、试验目的及原理:胶原蛋白是细胞外基质最重要的组成成份,使皮肤具有伸展性,可以补充皮肤各层所需的营养。随着年龄的增长和外界环境的影响,一方面胶原蛋白的合成能力逐渐降低,另一方面体内胶原蛋白酶的产生增多,蛋白降解加速,最终导致皮肤表层变薄,失去水分和弹性,形成皱纹。因此,降低体内胶原蛋白酶的产生速度或抑制其活性,或者促进皮肤胶原蛋白的合成能力均有助于减缓皮肤皱纹的产生或使皱纹变得不明显。同时,及时给皮肤补充水分,也有助于保持皮肤屏障正常,促进抗皱的效果。人真皮成纤维细胞能在体内合成Ⅰ型前胶原并分泌至胞外。Ⅰ型前胶原在末端前胶原肽酶的作用下,端肽分离后,聚合形成胶原纤维。因此,人真皮成纤维细胞可以作为研究化妆品促进Ⅰ型胶原蛋白合成的细胞模型,通过测定给药后,空白组与实验组Ⅰ型胶原蛋白含量上调率,评价受试物是否具有促进胶原蛋白合成的功效。
4.2、实验试剂与材料:DMEM基础培养基;胎牛血清;胰蛋白酶/EDTA溶液;PBS;MTT;人Ⅰ型胶原蛋白ELISA试剂盒;
4.3、主要仪器设备:二氧化碳培养箱;倒置显微镜;水平离心机;酶标仪;紫外交联仪。
4.4、实验方法:调整HFF-1细胞悬液浓度加入96孔板中,37℃、5%CO2条件下培养24h。弃去旧培养基,用UVB诱导造模,辐照结束后每孔加入100μL含样品的DMEM培养基,同时设培养基空白对照组和含TGF-β的培养基为阳性对照组,置于37℃、5%CO2条件下培养24h±2h。培养结束后,弃去细胞上清液,反复冻融细胞,收集细胞冻融液,按照ELISA试剂盒说明书进行人I型胶原蛋白含量测定。
4.5、结果计算:以标准品浓度为横坐标,OD450值为纵坐标,制作标准曲线,根据样品的OD450值,带入标准曲线,可得实验组胶原蛋白的含量。最终取各组3个复孔的平均值作为最终胶原蛋白结果。
用GraphPadPrism或其他统计学软件进行统计及显著性分析,计算P值,P<0.05表示具有显著性差异,否则无统计学差异。
胶原蛋白上调率计算公式:上调率(%)=(T/C-1)×100%
其中:T——实验组胶原蛋白平均值
C——空白/溶剂组胶原蛋白平均值
4.6、结果判定:每批次实验均设置阳性对照和空白对照。当阳性对照组的蛋白含量与空白对照组相比上调率≥20%,且组间复孔的OD值的变异系数CV值≤20%时,试验有效。样品组的胶原蛋白含量与空白对照相比,具有显著性差异(P<0.05),且样品组的胶原蛋白含量均高于空白组时,可判定样品具有抗皱功效,否则样品判为无抗皱功效。
表10、Ⅰ型胶原蛋白含量测定结果表
结合细胞抗皱功效测试,从实施例1-4与对比例1结果看出中和比不中和的胶原蛋白上调率更高,说明抗皱效果更佳。
上述实施例为本发明较佳的实施方式,但本发明的实施方式并不受上述实施例的限制,其他的任何未背离本发明的精神实质与原理下所作的改变、修饰、替代、组合、简化,均应为等效的置换方式,都包含在本发明的保护范围之内。
Claims (10)
1.一种应用二棕榈酰羟脯氨酸的方法,其特征在于,所述方法为将二棕榈酰羟脯氨酸以中和形式应用于组合物中。
2.一种应用二棕榈酰羟脯氨酸的组合物,其特征在于,所述组合物中的二棕榈酰羟脯氨酸以中和形式应用,按重量份数计包含以下组分:油类0.1-50份、二棕榈酰羟脯氨酸0.08-5份、螯合剂0.001-0.2份、保湿剂0.01-30份、增稠剂0.01-5.0份、中和剂0.001-7.5份、防腐剂0.01-3份以及水20-99份。
3.根据权利要求2所述的一种应用二棕榈酰羟脯氨酸的组合物,其特征在于,所述组合物中二棕榈酰羟脯氨酸与中和剂的的重量比为1:(0.002-2.5)。
4.根据权利要求2所述的一种应用二棕榈酰羟脯氨酸的组合物,其特征在于,按重量份数计还包括聚硅氧烷0.01-20份。
5.根据权利要求2所述的一种应用二棕榈酰羟脯氨酸的组合物,其特征在于,按重量份数计还包含脂肪醇0.01-10份。
6.根据权利要求2所述的一种应用二棕榈酰羟脯氨酸的组合物,其特征在于,按重量份数计还包含脂肪酸0.01-5份。
7.根据权利要求4所述的一种应用二棕榈酰羟脯氨酸的组合物,其特征在于,所述聚硅氧烷为环五聚二甲基硅氧烷、聚二甲基硅氧烷、环己硅氧烷、聚二甲基硅氧烷醇、聚甲基硅倍半氧烷、聚二甲基硅氧烷交联聚合物、辛基聚甲基硅氧烷、乙烯基聚二甲基硅氧烷交联聚合物、苯基聚三甲基硅氧烷、硬脂基聚二甲硅氧烷、二苯基甲硅烷氧基苯基聚三甲基硅氧烷、丙烯酸(酯)类/聚三甲基硅氧烷甲基丙烯酸酯共聚物、乙烯基聚二甲基硅氧烷/聚甲基硅氧烷硅倍半氧烷交联聚合物、鲸蜡基聚二甲基硅氧烷、聚硅氧烷-11、聚甲基硅氧烷、二聚硅氧烷、甲基聚三甲基硅氧烷中的一种或多种。
8.根据权利要求5所述的一种应用二棕榈酰羟脯氨酸的组合物,其特征在于,所述脂肪醇为鲸蜡醇、硬脂醇、山嵛醇、鲸蜡硬脂醇、花生醇、椰油醇、C12-16醇、C14-22醇、C20-22醇中的一种或多种。
9.根据权利要求6所述的一种应用二棕榈酰羟脯氨酸的组合物,其特征在于,所述脂肪酸为月桂酸、棕榈酸、肉豆蔻酸、硬脂酸中的一种或多种。
10.根据权利要求3所述的一种应用二棕榈酰羟脯氨酸的组合物,其特征在于,所述中和剂为氢氧化钾、氢氧化钠、精氨酸、氨丁三醇、氨甲基丙醇、三乙醇胺、氨甲基丙二醇、二甲基乙醇胺、二乙基乙醇胺中的一种或多种。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210027595.4A CN114209607A (zh) | 2022-01-11 | 2022-01-11 | 一种应用二棕榈酰羟脯氨酸的方法及组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210027595.4A CN114209607A (zh) | 2022-01-11 | 2022-01-11 | 一种应用二棕榈酰羟脯氨酸的方法及组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114209607A true CN114209607A (zh) | 2022-03-22 |
Family
ID=80708123
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210027595.4A Pending CN114209607A (zh) | 2022-01-11 | 2022-01-11 | 一种应用二棕榈酰羟脯氨酸的方法及组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114209607A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115670944A (zh) * | 2022-11-04 | 2023-02-03 | 山东福瑞达生物股份有限公司 | 一种具有抗衰功效的微海绵及其制备方法和应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106581798A (zh) * | 2016-12-08 | 2017-04-26 | 温州医科大学附属第二医院 | 带t形三通的超声造影剂机械推注装置 |
CN109276518A (zh) * | 2018-11-20 | 2019-01-29 | 长沙黛西生物科技有限公司 | 不含乳化剂的修复抗衰面霜及其制备方法 |
CN112569133A (zh) * | 2020-12-31 | 2021-03-30 | 彭氏(惠州)实业发展有限公司 | 紧致抗皱精华霜及其制备方法 |
CN113749972A (zh) * | 2021-10-18 | 2021-12-07 | 上海新高姿化妆品有限公司 | 一种具有抗皱效果的组合物及其在化妆品中的应用 |
-
2022
- 2022-01-11 CN CN202210027595.4A patent/CN114209607A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106581798A (zh) * | 2016-12-08 | 2017-04-26 | 温州医科大学附属第二医院 | 带t形三通的超声造影剂机械推注装置 |
CN109276518A (zh) * | 2018-11-20 | 2019-01-29 | 长沙黛西生物科技有限公司 | 不含乳化剂的修复抗衰面霜及其制备方法 |
CN112569133A (zh) * | 2020-12-31 | 2021-03-30 | 彭氏(惠州)实业发展有限公司 | 紧致抗皱精华霜及其制备方法 |
CN113749972A (zh) * | 2021-10-18 | 2021-12-07 | 上海新高姿化妆品有限公司 | 一种具有抗皱效果的组合物及其在化妆品中的应用 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115670944A (zh) * | 2022-11-04 | 2023-02-03 | 山东福瑞达生物股份有限公司 | 一种具有抗衰功效的微海绵及其制备方法和应用 |
CN115670944B (zh) * | 2022-11-04 | 2023-11-10 | 山东福瑞达生物股份有限公司 | 一种具有抗衰功效的微海绵及其制备方法和应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9289460B2 (en) | Use of natural active substances in cosmetic or therapeutic compositions | |
CA2749750C (en) | Skin care compositions and methods of use thereof | |
KR101323487B1 (ko) | 항주름제 | |
CN106377488B (zh) | 一种具有保湿控油功效的护肤基质及其制备方法与应用 | |
US20120195923A1 (en) | Use of skin care compositions comprising laminariacea extract for treatment of skin aging signs | |
CN108379110B (zh) | 护肤组合物、护肤膏霜及其制备方法 | |
CN108434064A (zh) | 兼具皮肤抗炎袪痘和修复功能的护肤品 | |
CN112120986A (zh) | 一种眼部修护组合物及含有该组合物的眼霜 | |
CN110731923A (zh) | 增强的保湿化妆品组合物 | |
CN108379215B (zh) | 一种具有美白肌肤功效的冻干粉组合物和包含该冻干粉组合物的化妆品组合物 | |
US7459166B2 (en) | Cosmetic product containing mineral water for remineralizing and rejuvenating the skin | |
JP6850732B2 (ja) | 紅藻アクロカエティウム・モニリフォルメ(Acrochaetium moniliforme)の細胞を培養するための方法、そのバイオマスの抽出物を得るための方法および化粧料におけるその使用 | |
CN108524354A (zh) | 护肤组合物、护肤面膜及其制备方法 | |
CN115054530A (zh) | 一种具有保湿抗衰老功效的护肤组合物及其制备方法 | |
CN114209607A (zh) | 一种应用二棕榈酰羟脯氨酸的方法及组合物 | |
CN108904436B (zh) | 一种兼具抗炎、抗老化作用的抗污染护肤组合物 | |
CN113018228B (zh) | 一种抗衰老组合物、面霜及其制备方法 | |
EP1317489B1 (en) | A mixture of non-sulfated fucose-based oligosaccharides, a cosmetic or pharmaceutical composition comprising said mixture and its use in cosmetics or pharmacy | |
CN114099388B (zh) | 一种抗皱组合物其制备方法及其应用 | |
CN113749972B (zh) | 一种具有抗皱效果的组合物及其在化妆品中的应用 | |
CN102470091A (zh) | N-十六酰异亮氨酸作为人皮肤“丰盈”剂和/或“丰满”剂的用途 | |
KR101154772B1 (ko) | 대추 추출물 및 호두 추출물을 함유하는 피부 보습용화장료 조성물 | |
CN113662876A (zh) | 多肽美颜精华液以及制备方法 | |
KR102089290B1 (ko) | 피부 주름 개선 및 탄력 증진을 위한 화장료 조성물 | |
CN112675063A (zh) | 一种含pdrn的嫩肤抗皱组合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220322 |